Dr. Anthony Krajcer, a rheumatologist at The Polyclinic Madison Center, is currently conducting a national research study comparing secukinumab (Cosentyx®) to adalimumab (Humira®) in patients with psoriatic arthritis. Both products are FDA-approved for the treatment of psoriatic arthritis symptoms.
About Psoriatic Arthritis
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis - a condition that features red patches of skin topped with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but the joint problems can sometimes begin before skin lesions appear.
Joint pain, stiffness, and swelling are the main symptoms of psoriatic arthritis. They can affect any part of the body, including the fingertips and spine, and can range from relatively mild to severe. In both psoriasis and psoriatic arthritis, disease flares may alternate with periods of remission.
Who is Eligible to Participate in the Study?
To be eligible for the study, patients must be 18 years or older and have psoriatic arthritis with symptoms for at least the past six months.
Participants who qualify and agree to join the study will receive individual care and assessments from a specialized health care provider. Study medicine and medical care will be provided at no cost. Reimbursement for completed study visits will also be provided.
For additional information about the study, please contact the study coordinator at email@example.com or 206-320-6752.